Tadalafil Tablet, Film Coated
Product Images NDC 82804-224

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 82804-224). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 01)

Chemical structure diagram of tadalafil, showing its molecular framework with labeled atoms and bonds characteristic of the active pharmaceutical ingredient.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 02)

This image contains four line graphs depicting the difference in blood pressure (BP) between tadalafil and placebo over time. The graphs show changes in standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP, with time measured in hours on the x-axis and BP difference in mmHg on the y-axis.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 03)

Two line graphs depicting the effects on systolic blood pressure over 24 hours post-dose. The top graph shows standing systolic blood pressure changes for tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg. The bottom graph presents supine systolic blood pressure changes over the same period for the same treatments.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 04)

A line graph depicting changes in systolic blood pressure (mmHg) over time after administration of tadalafil or placebo, combined with doxazosin. The x-axis represents time in hours, and the y-axis shows systolic blood pressure changes. Four conditions are compared: 20 mg tadalafil at 08:00, placebo at 08:00, 20 mg tadalafil at 20:00, and placebo at 20:00, each with 8 mg daily doxazosin.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 05)

A line graph showing plasma tadalafil concentration (mcg/L) over time (hours) following different dosing regimens: a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg doses after 5 days of administration. Concentration values decline over time for each dosing scenario with error bars indicating variability.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 06)

A line graph showing change from baseline in IPSS total score over 12 weeks of treatment comparing Tadalafil 5 mg and placebo. The x-axis represents duration of treatment in weeks, and the y-axis represents change in IPSS total score. Tadalafil shows a greater decrease in score than placebo over time, with a significant difference indicated at p<0.01.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 07)

A line graph comparing the change from baseline in IPSS total score over a 12-week treatment period between Tadalafil 5 mg and placebo groups. The x-axis shows the duration of treatment in weeks (0, 1, 4, 8, 12), and the y-axis shows the change from baseline. Tadalafil shows a greater decrease in IPSS score over time compared to placebo, with statistical significance indicated at week 4.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 08)

A line graph depicting the least-squares mean change from baseline over a 26-week therapy period comparing tadalafil/finasteride versus placebo/finasteride. The y-axis shows the mean change values, and the x-axis shows weeks of therapy at intervals 0, 4, 12, and 26. Statistical significance markers (a p<0.001, b p<0.05) are included for data points.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 09)

A line graph comparing the change from baseline in IPSS Total Score over a 12-week treatment period between tadalafil 5 mg and placebo groups. The x-axis shows treatment duration in weeks, and the y-axis shows changes in the score, with tadalafil demonstrating a greater score reduction than placebo over time.*

FDA Label Image

Unichem Logo (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 10)

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 11)

FDA Label Image

82804-224-30 (Image 01)

Label for Tadalafil 10 mg film-coated tablets by Proficient Rx LP, NDC 82804-224-30. The package contains 30 light orange, almond-shaped tablets, debossed with "288" on one side and "U" on the other. Manufacturer is Unichem Laboratories Ltd., India. Storage instructions and additional lot and expiration placeholders are included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.